Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Issue 5 (16th April 2021)

• Record Type: Journal Article
• Authors: Holkova, Beata; Shafer, Danielle; Yazbeck, Victor; Dave, Sandeep; Bose, Prithviraj; Tombes, Mary Beth; Shrader, Ellen; Wan, Wen; Bandyopadhyay, Dipankar; Weir, Caryn; Collins, Elizabeth B.; Garnett, Amanda; Kmieciak, Maciej; Roberts, John D.; Garcia-Manero, Guillermo; Grant, Steven
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 5(2021)
• Page Start: 1187
• Page End: 1194
• Publication Date: 2021-04-16
• Subjects: Acute leukemia -- belinostat -- bortezomib -- myelodysplastic syndrome -- phase 1 clinical trial; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1861270
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We report the results of a phase 1 dose-escalation study of belinostat and bortezomib in adult patients with acute leukemia or MDS or CML with blast crisis. Thirty-eight patients received IV belinostat days 1-5 and 8-12 with IV bortezomib days 1, 4, 8, and 11 every 21 days. QTc prolongation was the only identified DLT. The RP2Ds were 1.3 mg/m 2 bortezomib and 1000 mg/m 2 belinostat. One patient with highly refractory MLL-ENL rearranged biphenotypic AML with multiple karyotypic aberrations had a complete pathologic and karyotypic response. One patient with post-MPN AML remained on study with stable disease (SD) for 32 cycles. Whole-exome sequencing revealed no aberrations in the first patient and a hyper-mutator genotype in the second. Eighteen patients had a best response of SD. We conclude that this treatment strategy is feasible but has limited activity in this population. Nevertheless, the factors that predict exceptional responses to this strategy warrant further investigation.